300 related articles for article (PubMed ID: 33001338)
1. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y; Hikita H; Mochida S; Kawada N; Enomoto N; Ido A; Yoshiji H; Miki D; Hiasa Y; Takikawa Y; Sakamori R; Kurosaki M; Yatsuhashi H; Tateishi R; Ueno Y; Itoh Y; Yamashita T; Kanto T; Suda G; Nakamoto Y; Kato N; Asahina Y; Matsuura K; Terai S; Nakao K; Shimizu M; Takami T; Akuta N; Yamada R; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2021 Jan; 56(1):67-77. PubMed ID: 33001338
[TBL] [Abstract][Full Text] [Related]
2. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
[No Abstract] [Full Text] [Related]
4. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Chen CY; Su WW; Tseng KC; Lo CC; Liu CJ; Chen JJ; Peng CY; Shih YL; Yang SS; Huang CS; Huang KJ; Chang CY; Tsai MC; Kao WY; Fang YJ; Chen PY; Su PY; Tseng CW; Huang JJ; Lee PL; Lai HC; Hsieh TY; Chang CH; Huang YJ; Lee FJ; Chang CC; Kao JH
Gut; 2022 Jan; 71(1):176-184. PubMed ID: 33408122
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
[TBL] [Abstract][Full Text] [Related]
12. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
[No Abstract] [Full Text] [Related]
13. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Li J; Wu DB; Jiang W; Chen XB; Xiao GB; Wang YH; Wang ML; Tao YC; Chen EQ
Medicine (Baltimore); 2020 Oct; 99(43):e22726. PubMed ID: 33120769
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Liu CH; Chen CY; Su WW; Liu CJ; Lo CC; Huang KJ; Chen JJ; Tseng KC; Chang CY; Peng CY; Shih YL; Huang CS; Kao WY; Yang SS; Tsai MC; Wu JH; Chen PY; Su PY; Hwang JJ; Fang YJ; Lee PL; Tseng CW; Lee FJ; Lai HC; Hsieh TY; Chang CC; Chang CH; Huang YJ; Kao JH
Clin Mol Hepatol; 2021 Oct; 27(4):575-588. PubMed ID: 34255961
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH
Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
